Pharmacogenomic Approach to Selecting Antiplatelet Therapy in Patients With Acute Coronary Syndromes: The PHARMCLO Trial.

doi:10.1016/j.jacc.2018.02.029

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Community

Back to search

Article

Pharmacogenomic Approach to Selecting Antiplatelet Therapy in Patients With Acute Coronary Syndromes: The PHARMCLO Trial.

Journal of the American College of Cardiology - 1 May 2018

Notarangelo Francesca Maria, Maglietta Giuseppe, Bevilacqua Paola, Cereda Marco, Merlini Piera Angelica, Villani Giovanni Quinto, Moruzzi Paolo, Patrizi Giampiero, Malagoli Tagliazucchi Guidantonio, Crocamo Antonio, Guidorossi Angela, Pigazzani Filippo, Nicosia Elisa, Paoli Giorgia, Bianchessi Marco, Comelli Mario Angelo, Caminiti Caterina, Ardissino Diego

Abstract excerpt

BACKGROUND: Although clopidogrel is still frequently used in patients with acute coronary syndromes (ACS), its efficacy is hampered by interpatient response variability caused by genetic polymorphisms associated with clopidogrel's metabolism. OBJECTIVES: The goal of this study was to evaluate whether selecting antiplatelet therapy (clopidogrel, prasugrel, or ticagrelor) on the basis of a patient's genetic and...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Acute Coronary Syndrome

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Aged

Share to Aged, 80 and over

Share to ATP Binding Cassette Transporter, Subfamily B

Share to Cytochrome P-450 CYP2C19

Share to Pharmacogenomic Testing

Share to Platelet Aggregation Inhibitors

Share to Receptors, Purinergic P2Y12

Source

Open in PubMed

Identifiers

PMID: 29540324
DOI: 10.1016/j.jacc.2018.02.029

Genes

ABCB1

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Pharmacogenomic Approach to Selecting Antiplatelet Therapy in Patients With Acute Coronary Syndromes: The PHARMCLO Trial.PMID 29540324Read ↗

A prospective randomized evaluation of a pharmacogenomic approach to antiplatelet therapy among patients with ST-elevation myocardial infarction: the RAPID STEMI study.Semantic proximity Read ↗

CYP2C19 genotype-guided antiplatelet therapy in ST-segment elevation myocardial infarction patients-Rationale and design of the Patient Outcome after primary PCI (POPular) Genetics study.Semantic proximity Read ↗

Value of platelet pharmacogenetics in common clinical practice of patients with ST-segment elevation myocardial infarction.Semantic proximity Read ↗

A real-world study of clopidogrel therapy in patients with acute coronary syndrome undergoing percutaneous coronary intervention guided by individualized metabolic typesSemantic proximity Read ↗

The Clinical Implementation of CYP2C19 Genotyping in Patients with an Acute Coronary Syndrome: Insights From the FORCE-ACS Registry.Semantic proximity Read ↗

A meta-analysis of efficacy and safety of genotype-guided versus standard of care treatment strategies in selecting antiplatelet therapy in patients with acute coronary syndrome.Semantic proximity Read ↗

Cost-effectiveness of cytochrome P450 2C19 genotype screening for selection of antiplatelet therapy with clopidogrel or prasugrel.Semantic proximity Read ↗

Genotype-Phenotype Association and Impact on Outcomes following Guided De-Escalation of Anti-Platelet Treatment in Acute Coronary Syndrome Patients: The TROPICAL-ACS Genotyping Substudy.Semantic proximity Read ↗

Genotype- and phenotype-directed antiplatelet therapy selection in patients with acute coronary syndromes.Semantic proximity Read ↗

Implementing CYP2C19 Pharmacogenetic Testing for Personalized Antiplatelet Therapy: Findings From the QPGx-CARES Initiative.Semantic proximity Read ↗

Cost-effectiveness of genotype-guided and dual antiplatelet therapies in acute coronary syndrome.Semantic proximity Read ↗

The efficacy and safety of CYP2C19 genotype-guided antiplatelet therapy compared with conventional antiplatelet therapy in patients with acute coronary syndrome or undergoing percutaneous coronary intervention: A meta-analysis of randomized controlled trials.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.